| Nivolumab versus everolimus in advanced renal-cell carcinoma RJ Motzer, B Escudier, DF McDermott, S George, HJ Hammers, S Srinivas, ... New England Journal of Medicine 373 (19), 1803-1813, 2015 | 6034 | 2015 |
| Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma RJ Motzer, NM Tannir, DF McDermott, O Arén Frontera, B Melichar, ... New England Journal of Medicine 378 (14), 1277-1290, 2018 | 4086 | 2018 |
| Cabozantinib versus everolimus in advanced renal-cell carcinoma TK Choueiri, B Escudier, T Powles, PN Mainwaring, BI Rini, F Donskov, ... New England Journal of Medicine 373 (19), 1814-1823, 2015 | 1270 | 2015 |
| Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial RJ Motzer, BI Rini, DF McDermott, BG Redman, TM Kuzel, MR Harrison, ... Journal of clinical oncology 33 (13), 1430, 2015 | 1174 | 2015 |
| Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial TK Choueiri, B Escudier, T Powles, NM Tannir, PN Mainwaring, BI Rini, ... The lancet oncology 17 (7), 917-927, 2016 | 1047 | 2016 |
| Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas J Zeng, AP See, J Phallen, CM Jackson, Z Belcaid, J Ruzevick, N Durham, ... International Journal of Radiation Oncology* Biology* Physics 86 (2), 343-349, 2013 | 1014 | 2013 |
| Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised … RJ Motzer, BI Rini, DF McDermott, OA Frontera, HJ Hammers, ... The Lancet Oncology 20 (10), 1370-1385, 2019 | 725 | 2019 |
| Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth H Zhang, DZ Qian, YS Tan, KA Lee, P Gao, YR Ren, S Rey, H Hammers, ... Proceedings of the National Academy of Sciences 105 (50), 19579-19586, 2008 | 717 | 2008 |
| Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma TK Choueiri, P Tomczak, SH Park, B Venugopal, T Ferguson, YH Chang, ... New England Journal of Medicine 385 (8), 683-694, 2021 | 523 | 2021 |
| Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study HJ Hammers, ER Plimack, JR Infante, BI Rini, DF McDermott, LD Lewis, ... Journal of Clinical Oncology 35 (34), 3851, 2017 | 468 | 2017 |
| Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab DF McDermott, CG Drake, M Sznol, TK Choueiri, JD Powderly, DC Smith, ... Journal of clinical oncology 33 (18), 2013, 2015 | 458 | 2015 |
| Withaferin A is a potent inhibitor of angiogenesis R Mohan, H Hammers, P Bargagna-Mohan, X Zhan, C Herbstritt, A Ruiz, ... Angiogenesis 7, 115-122, 2004 | 431 | 2004 |
| Antagonists of PD-1 and PD-L1 in cancer treatment EJ Lipson, PM Forde, HJ Hammers, LA Emens, JM Taube, SL Topalian Seminars in oncology 42 (4), 587-600, 2015 | 329 | 2015 |
| Concurrent immune checkpoint inhibitors and stereotactic radiosurgery for brain metastases in non-small cell lung cancer, melanoma, and renal cell carcinoma L Chen, J Douglass, L Kleinberg, X Ye, AE Marciscano, PM Forde, ... International Journal of Radiation Oncology* Biology* Physics 100 (4), 916-925, 2018 | 302 | 2018 |
| Targeting tumor angiogenesis with histone deacetylase inhibitors L Ellis, H Hammers, R Pili Cancer letters 280 (2), 145-153, 2009 | 297 | 2009 |
| Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). A Amin, ER Plimack, JR Infante, MS Ernstoff, BI Rini, DF McDermott, ... Journal of Clinical Oncology 32 (15_suppl), 5010-5010, 2014 | 291 | 2014 |
| The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for … D Keizman, M Ish-Shalom, P Huang, MA Eisenberger, R Pili, H Hammers, ... European Journal of Cancer 48 (2), 202-208, 2012 | 257 | 2012 |
| Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial D Cella, V Grünwald, B Escudier, HJ Hammers, S George, P Nathan, ... The Lancet Oncology 20 (2), 297-310, 2019 | 254 | 2019 |
| Nivolumab versus everolimus in patients with advanced renal cell carcinoma: updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial RJ Motzer, B Escudier, S George, HJ Hammers, S Srinivas, SS Tykodi, ... Cancer 126 (18), 4156-4167, 2020 | 252 | 2020 |
| CheckMate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma B Escudier, P Sharma, DF McDermott, S George, HJ Hammers, S Srinivas, ... European urology 72 (6), 962-971, 2017 | 252 | 2017 |
